4-[[4-[[1-(4-chlorophenyl)cyclopropyl]amino]-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino]-N-[2-(dimethylamino)ethylsulfonyl]benzamide | 1360826-42-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 4-[[4-[[1-(4-chlorophenyl)cyclopropyl]amino]-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino]-N-[2-(dimethylamino)ethylsulfonyl]benzamide
• CAS: 1360826-42-1
• 化学式: C₂₅H₂₇ClF₃N₇O₄S
• 分子量: 614.048
• InChiKey: XAJIRGSNSNONDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  41
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  147
• 氢给体数：
  3
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 N-(2-aminoethylsulfonyl)-4-[[4-[[1-(4-chlorophenyl)cyclopropyl]amino]-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino]benzamide 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 反应 4.0h， 生成 4-[[4-[[1-(4-chlorophenyl)cyclopropyl]amino]-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino]-N-[2-(dimethylamino)ethylsulfonyl]benzamide
  参考文献：
  名称：

  Functionalized triazines as potent HCV entry inhibitors

  摘要：

  A series of potent and novel acylsulfonamide-bearing triazines were synthesized and the structure-activity relationships (SARs) as HCV entry inhibitors were evaluated. This acylsulfonamide series was derived from an early lead, 4-(4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzoic acid wherein the carboxylic acid was replaced with an acylsulfonamide moiety. This structural modification provided a class of compounds which projected an additional vector off the terminus of the acylsulfonamide functionality as a means to drive activity. This effort led to the discovery of potent analogues within this series that demonstrated sub-nanomolar EC50 values in the HCV pseudotype particle (HCVpp) assay. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.12.038

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012024373A1

  公开（公告）日：2012-02-23

  The disclosure provides compounds of formula (I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. (Formula (I))

  该披露提供了公式（I）的化合物，包括药用可接受的盐，以及使用这些化合物的组合物和方法。这些化合物对丙型肝炎病毒（HCV）具有活性，并可能对感染HCV的人有用。（公式（I））
• Compounds for the Treatment of Hepatitis C
  申请人：Sun Li-Qiang

  公开号：US20120213729A1

  公开（公告）日：2012-08-23

  The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

  本公开提供了I式化合物，其中包括药用可接受的盐，以及使用该化合物的组合物和方法。这些化合物对丙型肝炎病毒（HCV）具有活性，并可用于治疗HCV感染者。
• COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
  申请人：Bristol-Myers Squibb Company

  公开号：EP2606038B1

  公开（公告）日：2016-01-13
• US8765944B2
  申请人：——

  公开号：US8765944B2

  公开（公告）日：2014-07-01